[ad_1] RT @ThomasCiullaMD: Recently published, “Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Fu… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] RT @ThomasCiullaMD: Just published: Progress in the pharmacotherapy of uveitis: the art of personalized care https://t.co/4gQ6cbQogQ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
RT @RetinaToday: You are invited to attend a CME Symposium in Chicago in-person or virtual during the #AAO2022 Annual Meeting: Into the #S…
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] RT @ModernRetina: The Phase 2 Altitude study evaluates the efficacy, safety, and tolerability of suprachoroidal delivery of RGX-314 in pati… [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1] Just published, “Suprachoroidal delivery enables targeting, localization and durability of small molecule suspensions” in the Journal of Controlled Release, a high-impact leading journal on #drugdelivery systems & formulations! #suprachoroidal #retina https://t.co/25dGszj795 [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.
[ad_1]
Recently published, “Suprachoroidal Drug Delivery for Clinicians: Anatomic Principles, Clinical Data in Uveitis, and Future Directions”
This paper reviews #suprachoroidal space anatomy, biomechanics, microinjector, #Xipere, #genetherapy & other trials.
https://t.co/OXcGgMU7Fv
[ad_2]
Source by Thomas Ciulla, MD, MBA
[ad_1] Just published: Progress in the pharmacotherapy of uveitis: the art of personalized care https://t.co/4gQ6cbQogQ [ad_2] Source by Thomas Ciulla, MD, MBA Return to main website.